Form 4: CONMED EVP Shagory Receives Equity Awards

CONMED Corporation's EVP, Strategy & Corporate Development, Peter K. Shagory, was granted 9,282 Restricted Stock Units and 10,999 stock options under the company's 2025 Long-Term Incentive Plan.

Summary

• Peter K. Shagory, Executive Vice President, Strategy & Corporate Development at CONMED Corporation (CNMD), acquired 9,282 Restricted Stock Units (RSUs) and 10,999 stock options.
• The RSUs represent a contingent right to receive one share of common stock for each unit and were granted under the Company's 2025 Long-Term Incentive Plan.
• RSUs generally vest over a three-year period: 33% one year after the grant date, 33% in the second year, and 34% in the third year.
• The stock options were also granted under CONMED Corporation's 2025 Long-Term Incentive Plan with an exercise price of $45.79 per share.
• Stock options generally vest in equal amounts over a four-year period, with the first 25% vesting one year after the grant date.
• Both the RSUs and stock options have an expiration date of March 2, 2036.

Sentiment

Score: 6

Explanation: StockSavvy.ai views this as a neutral to slightly positive event. It's a routine disclosure of executive compensation, which is positive in that it aligns management incentives with shareholder value, but it does not indicate any new operational or financial performance.

Positives

• The grant of equity awards to a key executive aligns management's interests with those of shareholders, incentivizing long-term performance.
• The awards are part of the company's 2025 Long-Term Incentive Plan, indicating a structured approach to executive compensation and retention.

Future Outlook

The equity awards, granted under the 2025 Long-Term Incentive Plan, are designed to incentivize the executive for future performance over a multi-year period, suggesting a focus on sustained growth and value creation for CONMED Corporation.

Industry Context

StockSavvy.ai notes that the granting of equity awards like RSUs and stock options is a standard practice in the medical technology and healthcare industry for executive compensation. These long-term incentives are crucial for attracting and retaining top talent, aligning executive performance with shareholder returns, and fostering a long-term strategic vision within the company. This particular grant to a key strategic development executive suggests a continued emphasis on future growth initiatives.

Comparison to Industry Standards

• The use of a combination of Restricted Stock Units (RSUs) and stock options is a common structure for executive long-term incentive plans across the S&P 500, including peers in the medical device sector such as Stryker (SYK) and Zimmer Biomet (ZBH).
• Vesting periods of three to four years for equity awards are typical, aiming to ensure executive retention and alignment with multi-year strategic objectives.
• The exercise price of $45.79 for the options, likely based on the market price at the grant date, is standard practice to ensure options have intrinsic value only if the stock price appreciates.

Corporate Governance

Stakeholder Impact

• Shareholders: The equity awards are designed to align the interests of a key executive with those of shareholders, potentially leading to improved long-term company performance and stock appreciation.
• Employees: The long-term incentive plan can serve as a model for performance-based compensation, potentially influencing broader employee incentive structures.

Next Steps

• The Restricted Stock Units will begin vesting one year from the grant date, with subsequent vesting over a three-year period.
• The stock options will begin vesting one year from the grant date, with subsequent vesting over a four-year period.

Key Dates

Keywords

CONMED Corporation, CNMD, Restricted Stock Units, RSUs, Stock Options, Executive Compensation, Insider Transaction, Form 4, Long-Term Incentive Plan, Equity Awards